Literature DB >> 17671978

The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study.

Tsjerk A Wassenaar1, Wim J Quax, Alan E Mark.   

Abstract

The Death Receptor 5 (DR5), a member of tumor necrosis factor receptor (TNFR) superfamily of receptors, triggers apoptosis (programmed cell death) when stimulated by its tridentate ligand TRAIL. Until recently it was generally assumed that the activation of DR5 resulted from the recruitment of three independent receptor units, leading to the trimerization of intracellular domains. However, there is mounting evidence to suggest that, in the absence of ligand, such cytokine receptors primarily reside as preformed complexes. In this work, molecular dynamics simulations of the TRAIL-DR5 complex, the unbound receptor trimer and individual receptor monomers are compared to gain insight in the mechanism of activation. The results suggest that, in the absence of TRAIL, DR5 has a strong propensity to self-associate and that this is primarily mediated through interactions of the membrane proximal domains. The association of the free receptors leads to a loss of the threefold symmetry found within the receptor-ligand complex. The simulations suggest that the primary role of TRAIL is to induce threefold-symmetry within the DR5 complex and to constrain the receptor to a specific conformation. The implications of this in terms of the mechanism by which the receptor switches from an inactive to an active state are discussed. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17671978     DOI: 10.1002/prot.21541

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  9 in total

1.  Hexapeptide fragment of carcinoembryonic antigen which acts as an agonist of heterogeneous ribonucleoprotein M.

Authors:  Nicholas Y Palermo; Peter Thomas; Richard F Murphy; Sándor Lovas
Journal:  J Pept Sci       Date:  2012-03-06       Impact factor: 1.905

Review 2.  Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Authors:  Hope M Amm; Patsy G Oliver; Choo Hyung Lee; Yufeng Li; Donald J Buchsbaum
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

3.  Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.

Authors:  Marie P Piechocki; Gen Sheng Wu; Richard F Jones; Jennifer B Jacob; Heather Gibson; Stephen P Ethier; Judith Abrams; Hideo Yagita; K Venuprasad; Wei-Zen Wei
Journal:  Int J Cancer       Date:  2012-04-24       Impact factor: 7.396

4.  Molecular dynamics study of the effect of active site protonation on Helicobacter pylori 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase.

Authors:  Mustafa Tekpinar; Ahmet Yildirim; Tsjerk A Wassenaar
Journal:  Eur Biophys J       Date:  2015-08-08       Impact factor: 1.733

5.  Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.

Authors:  Claire L Dobson; Sarah Main; Philip Newton; Matthieu Chodorge; Karen Cadwallader; Robin Humphreys; Vivian Albert; Tristan J Vaughan; Ralph R Minter; Bryan M Edwards
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

6.  Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.

Authors:  Peng Zhang; Yong Zheng; Juan Shi; Yaxi Zhang; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

7.  A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.

Authors:  Ali Alejo; Margarida Saraiva; Maria Begoña Ruiz-Argüello; Abel Viejo-Borbolla; Mar Fernández de Marco; Francisco Javier Salguero; Antonio Alcami
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

8.  Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.

Authors:  Rosa Martín-Pérez; Rosario Yerbes; Rocío Mora-Molina; Ana Cano-González; Joaquín Arribas; Massimiliano Mazzone; Abelardo López-Rivas; Carmen Palacios
Journal:  Oncotarget       Date:  2017-10-03

Review 9.  Receptor Specificity Engineering of TNF Superfamily Ligands.

Authors:  Fengzhi Suo; Xinyu Zhou; Rita Setroikromo; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.